drugset

drugset / Trial / NCT03997435

FOLFOXIRI With or Without Intensification for Rectal Cancer

NCT03997435 ↗

Phase 2 Active not recruiting 72 enrolled CCTU

RandomizedParallel-groupOpen-labelTreatment

Summary

Pathologic complete response rate

Timeline

Start: 2019-09-10
Primary completion: 2026-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Capecitabine	Small molecule	—	—

Indications